Human Serum-derived α-synuclein Auto-antibodies Mediate NMDA Receptor-dependent Degeneration of CNS Neurons

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2024 Feb 28

PMID 38419079

Authors

Pretty Garg

Franziska Wurtz

Fabian Hobbie

Klemens Buttgereit

Abhishek Aich

Kristian Leite

Peter Rehling

Sebastian Kugler

Mathias Bahr

Affiliations

Soon will be listed here.

Abstract

Background: Presence of autoantibodies against α-synuclein (α-syn AAb) in serum of the general population has been widely reported. That such peripheral factors may be involved in central nervous system pathophysiology was demonstrated by detection of immunoglobulins (IgGs) in cerebrospinal fluid and brain of Parkinson's disease (PD) patients. Thus, blood-borne IgGs may reach the brain parenchyma through an impaired blood-brain barrier (BBB).

Findings: The present study aims to evaluate the patho-physiological impact of α-syn AAbs on primary brain cells, i.e., on spontaneously active neurons and on astrocytes. Exposure of neuron-astrocyte co-cultures to human serum containing α-syn AAbs mediated a dose-dependent reduction of spontaneous neuronal activity, and subsequent neurodegeneration. Removal specifically of α-syn AAbs from the serum prevented neurotoxicity, while purified, commercial antibodies against α-syn mimicked the neurodegenerative effect. Mechanistically, we found a strong calcium flux into neurons preceding α-syn AAbs-induced cell death, specifically through NMDA receptors. NMDA receptor antagonists prevented neurodegeneration upon treatment with α-syn (auto)antibodies. α-syn (auto)antibodies did not affect astrocyte survival. However, in presence of α-syn, astrocytes reacted to α-syn antibodies by secretion of the chemokine RANTES.

Conclusion: These findings provide a novel basis to explain how a combination of BBB impairment and infiltration of IgGs targeting synuclein may contribute to neurodegeneration in PD and argue for caution with α-syn immunization therapies for treatment of PD.

References

Kuhn I, Rogosch T, Schindler T, Tackenberg B, Zemlin M, Maier R . Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood. J Neuroimmunol. 2018; 315:33-39. DOI: 10.1016/j.jneuroim.2017.12.003. View

Psol M, Guerin Darvas S, Leite K, Mahajani S, Bahr M, Kugler S . Dementia with Lewy bodies-associated ß-synuclein mutations V70M and P123H cause mutation-specific neuropathological lesions. Hum Mol Genet. 2021; 30(3-4):247-264. DOI: 10.1093/hmg/ddab036. View

Burre J, Sharma M, Sudhof T . Cell Biology and Pathophysiology of α-Synuclein. Cold Spring Harb Perspect Med. 2017; 8(3). PMC: 5519445. DOI: 10.1101/cshperspect.a024091. View

Trudler D, Sanz-Blasco S, Eisele Y, Ghatak S, Bodhinathan K, Akhtar M . α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss. J Neurosci. 2021; 41(10):2264-2273. PMC: 8018774. DOI: 10.1523/JNEUROSCI.1871-20.2020. View

Kortekaas R, Leenders K, van Oostrom J, Vaalburg W, Bart J, Willemsen A . Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005; 57(2):176-9. DOI: 10.1002/ana.20369. View

Braczynski A, Sevenich M, Gering I, Kupreichyk T, Agerschou E, Kronimus Y . Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo. Biomolecules. 2022; 12(3). PMC: 8946620. DOI: 10.3390/biom12030469. View

Davies J, Francis A, Jones A, Watkins J . 2-Amino-5-phosphonovalerate (2APV), a potent and selective antagonist of amino acid-induced and synaptic excitation. Neurosci Lett. 1981; 21(1):77-81. DOI: 10.1016/0304-3940(81)90061-6. View

Lakos A, Ferenczi E, Komoly S, Granstrom M . Different B-cell populations are responsible for the peripheral and intrathecal antibody production in neuroborreliosis. Int Immunol. 2005; 17(12):1631-7. DOI: 10.1093/intimm/dxh343. View

Tang P, Chong L, Li X, Liu Y, Liu P, Hou C . Correlation between serum RANTES levels and the severity of Parkinson's disease. Oxid Med Cell Longev. 2015; 2014:208408. PMC: 4283268. DOI: 10.1155/2014/208408. View

10.

Maetzler W, Apel A, Langkamp M, Deuschle C, Dilger S, Stirnkorb J . Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. PLoS One. 2014; 9(2):e88604. PMC: 3931625. DOI: 10.1371/journal.pone.0088604. View

11.

Diogenes M, Dias R, Rombo D, Miranda H, Maiolino F, Guerreiro P . Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012; 32(34):11750-62. PMC: 6703775. DOI: 10.1523/JNEUROSCI.0234-12.2012. View

12.

Hardingham G, Bading H . Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010; 11(10):682-96. PMC: 2948541. DOI: 10.1038/nrn2911. View

13.

Chiu Y, Wu K, Yu S, Wu K, Wang Y, Lin J . Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein. PLoS One. 2023; 18(9):e0291927. PMC: 10513202. DOI: 10.1371/journal.pone.0291927. View

14.

Greenland J, Williams-Gray C, Barker R . The clinical heterogeneity of Parkinson's disease and its therapeutic implications. Eur J Neurosci. 2018; 49(3):328-338. DOI: 10.1111/ejn.14094. View

15.

Mahajani S, Raina A, Fokken C, Kugler S, Bahr M . Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors. Cell Death Dis. 2019; 10(12):898. PMC: 6881336. DOI: 10.1038/s41419-019-2133-9. View

16.

Yamada K, Iwatsubo T . Extracellular α-synuclein levels are regulated by neuronal activity. Mol Neurodegener. 2018; 13(1):9. PMC: 5822605. DOI: 10.1186/s13024-018-0241-0. View

17.

Veldkamp C, Koplinski C, Jensen D, Peterson F, Smits K, Smith B . Production of Recombinant Chemokines and Validation of Refolding. Methods Enzymol. 2016; 570:539-65. PMC: 4811038. DOI: 10.1016/bs.mie.2015.09.031. View

18.

Fauser M, Lohle M, Ebersbach G, Odin P, Fuchs G, Jost W . Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. J Parkinsons Dis. 2015; 5(4):737-41. DOI: 10.3233/JPD-150656. View

19.

von Coelln R, Shulman L . Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr Opin Neurol. 2016; 29(6):727-734. DOI: 10.1097/WCO.0000000000000384. View

20.

Kugler S, Meyn L, Holzmuller H, Gerhardt E, Isenmann S, Schulz J . Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol Cell Neurosci. 2001; 17(1):78-96. DOI: 10.1006/mcne.2000.0929. View